传统疗法和潜在的心脏病治疗药物:为什么不能两者兼而有之?
Lauren Rae Gladwell1, Chidinma Ahiarah1, Shireen Rasheed1
1Department of Pharmaceutical Sciences, Texas A&M Irma Lerma Rangel College of Pharmacy, 1114 TAMU, College Station, TX 77843, USA.
Life (Basel, Switzerland)
|January 23, 2024
概括
心血管疾病 (CVD) 的治疗方法正在发展,超越了传统方法. 表观遗传疗法提供了一种有希望的新方法,通过修改基因表达来解决心血管疾病的根本原因,从而有可能改善患者的治疗结果.
科学领域:
- 遗传学和分子生物学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因,严重影响生活质量和生产力.
- 普遍存在的风险因素包括肥胖,2型糖尿病,高血压和高脂血症,这些都对心血管疾病的高负担有所贡献.
- 目前的传统心血管疾病干预措施提供了症状缓解,但产生了巨大的经济成本,可能需要终身处方.
研究的目的:
- 审查导致心血管疾病的各种风险因素.
- 讨论传统心血管药物的当前前前景和局限性.
- 专注于表观遗传疗法作为心血管疾病的替代或补充治疗的潜力.
主要方法:
- 本综述综合了有关心血管疾病风险因素和传统治疗方法的当前文献.
- 它探讨了新兴的表观遗传学领域及其在心血管医学中的应用.
- 该审查的重点是了解表观遗传修饰如何可以针对心血管疾病的治疗益处.
主要成果:
- 表观遗传干预通过改变基因组组织而不是DNA序列来调节基因表达.
- 表观遗传变化是可遗传的,可逆的,受到环境因素的影响,提供了动态的治疗潜力.
- 表观遗传方法提供了一种新的策略,用于解决各种心血管疾病的潜在病理生理学.
结论:
- 表观遗传疗法为心血管医学提供了新的前沿,有可能克服传统治疗方法的局限性.
- 通过向表观遗传水平,这些新的干预措施可以提供更全面和可持续的CVD管理.
- 对表观遗传疗法的进一步研究可能会导致改善治疗策略,为心血管疾病患者提供更好的生活质量的希望.
相关概念视频
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
518
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
518
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
449
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
449
01:16Antianginal Drugs: Nitrates and β-Blockers
593
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
593
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525